1. Home
  2. PLG vs PMN Comparison

PLG vs PMN Comparison

Compare PLG & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Platinum Group Metals Ltd. (Canada)

PLG

Platinum Group Metals Ltd. (Canada)

HOLD

Current Price

$1.28

Market Cap

167.4M

Sector

N/A

ML Signal

HOLD

Logo ProMIS Neurosciences Inc. (ON)

PMN

ProMIS Neurosciences Inc. (ON)

HOLD

Current Price

$12.22

Market Cap

136.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLG
PMN
Founded
2000
2004
Country
Canada
Canada
Employees
N/A
N/A
Industry
Pharmaceuticals and Biotechnology
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
167.4M
136.2M
IPO Year
2002
2022

Fundamental Metrics

Financial Performance
Metric
PLG
PMN
Price
$1.28
$12.22
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$42.67
AVG Volume (30 Days)
888.1K
99.3K
Earning Date
04-10-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.18
$0.29
52 Week High
$4.04
$27.40

Technical Indicators

Market Signals
Indicator
PLG
PMN
Relative Strength Index (RSI) 41.11 45.45
Support Level $1.25 $9.87
Resistance Level $1.48 $14.40
Average True Range (ATR) 0.07 1.37
MACD 0.01 -0.23
Stochastic Oscillator 39.13 5.22

Price Performance

Historical Comparison
PLG
PMN

About PLG Platinum Group Metals Ltd. (Canada)

Platinum Group Metals Ltd is a development-stage company, conducts work on mineral properties it has staked or acquired by way of option agreements in the Republic of South Africa. Key metals of economic interest on the company's mineral properties include platinum, palladium, rhodium, gold, copper, and nickel. The company operates in one segment, the development of the Waterberg Project in South Africa, and geographically in Canada and South Africa.

About PMN ProMIS Neurosciences Inc. (ON)

ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.

Share on Social Networks: